# Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

> **NCT01829711** · PHASE3 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 80 (actual)

## Conditions studied

- Leukemia, Hairy Cell

## Interventions

- **DRUG:** Moxetumomab pasudotox
- **DRUG:** IV Bag Protectant for Moxetumomab pasudotox

## Key facts

- **NCT ID:** NCT01829711
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-29
- **Primary completion:** 2017-05-24
- **Final completion:** 2019-04-29
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829711, "Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01829711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*